Volume 5, Issue 5, September 2020, Page: 150-154
Evolution of Resistance to Fluoroquinolones of Uropathogenic Strains of Escherichia coli Isolated at the University Hospital of Marrakesh, Morocco
Saida Ed-dyb, Microbiology Department, Mohammed VI University Hospital, Marrakesh, Morocco
Khadija Ait Zirri, Microbiology Department, Mohammed VI University Hospital, Marrakesh, Morocco
Fatima Babokh, Microbiology Department, Mohammed VI University Hospital, Marrakesh, Morocco
Raihane Bahri, Microbiology Department, Mohammed VI University Hospital, Marrakesh, Morocco
Asmaa Lamrani, Microbiology Department, Mohammed VI University Hospital, Marrakesh, Morocco
Nabila Soraa, Microbiology Department, Mohammed VI University Hospital, Marrakesh, Morocco
Received: Sep. 19, 2020;       Accepted: Oct. 16, 2020;       Published: Oct. 27, 2020
DOI: 10.11648/j.ajlm.20200505.14      View  63      Downloads  17
Abstract
Background: Urinary tract infection is a common pathology in practice. The most implicated bacterial species is Escherichia coli. Fluoroquinolones occupy a privileged place among the molecules most prescribed in the treatment of these infections. Objective: determine the fluoroquinolone resistance profile of uropathogenic Escherichia coli strains at University Hospital Med VI of Marrakesh and analyze the evolution of this resistance over time in these isolates. Materials and methods: Descriptive study, over a period of 5 years (January 1, 2013 - December 31, 2017), covering all uropathogenic strains of E.coli isolated from outpatients and hospitalized at the University Hospital of Marrakesh. The samples were processed and analyzed in the Microbiology laboratory of the University Hospital. Results: During the study period, 1411 strains of uropathogenic E.coli were included. Women were mostly affected (68%). The prevalence of urinary tract infection was 22%. The number of strains studied and the resistance rates were calculated by combining the resistant strains and the intermediate strains. Resistance to ciprofloxacin increased from 16% in 2013 to 32% in 2017. An increase with age has been demonstrated for resistance to fluoroquinolones. Extended spectrum beta-lactamase production significantly affected the resistance rate to fluoroquinolones in E.coli (24% in C3G-sensitive strains and 56% in ESBL strains). Conclusion: This study demonstrates the serious emergence of the resistance of uropathogenic E.coli strains to fluoroquinolones, hence the interest of revising the empirical treatment of urinary tract infections in our country and monitoring use antibiotics to control the diffusion of quinolone resistance in E.coli.
Keywords
E.coli, Fluoroquinolones, Resistance, Uropathogenic
To cite this article
Saida Ed-dyb, Khadija Ait Zirri, Fatima Babokh, Raihane Bahri, Asmaa Lamrani, Nabila Soraa, Evolution of Resistance to Fluoroquinolones of Uropathogenic Strains of Escherichia coli Isolated at the University Hospital of Marrakesh, Morocco, American Journal of Laboratory Medicine. Vol. 5, No. 5, 2020, pp. 150-154. doi: 10.11648/j.ajlm.20200505.14
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Betsy Foxman, «Urinary Tract Infection Syndromes», Infectious Disease Clinics of North America 28, no 1 (mars 2014): 1‑13
[2]
Deepak S. Ipe et al., «Asymptomatic Bacteriuria: Prevalence Rates of Causal Microorganisms, Etiology of Infection in Different Patient Populations, and Recent Advances in Molecular Detection », FEMS Microbiology Letters 346, no 1 (septembre 2013): 1-10.
[3]
David C. Hooper, «Mechanisms of Action of Antimicrobials: Focus on Fluoroquinolones», Clinical Infectious Diseases 32, no Supplement_1 (15 mars 2001): S9‑15.
[4]
V. de Lastours et B. Fantin, «Résistance aux fluoroquinolones en 2013 : quel impact pour l’interniste ?», La Revue de Médecine Interne 35, no 9 (septembre 2014): 601‑8.
[5]
S. Allali et al., «Résistance aux fluoroquinolones en urologie : prévalence, évolution et alternatives thérapeutiques à propos des principaux germes uropathogènes retrouvés entre 2004 et 2014», /data/revues/11667087/v25i13/S1166708715004029/, 29 octobre 2015.
[6]
M. C. El Bouamri et al., «Évolution récente du profil épidémiologique des entérobactéries uropathogènes productrices de β-lactamases à spectre élargi à Marrakech, Maroc», Progrès en Urologie 24, no 7 (juin 2014): 451‑55.
[7]
Société Française de Microbiologie CASFM / EUCAST: Ed; 2019.
[8]
B. Fantin, «Résistance aux fluoroquinolones chez les entérobactéries : quelles conséquences pour le traitement empirique ?», Antibiotiques 11, no 2 (mai 2009): 63‑64.
[9]
Ana C. Gales et al., «Urinary Tract Infection Trends in Latin American Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000)», Diagnostic Microbiology and Infectious Disease 44, no 3 (novembre 2002): 289‑99.
[10]
Eric Garnotel et al., «Sensibilité aux antibiotiques d’ Escherichia coli isolé des infections urinaires communautaires : étude AFORCOPI-BIO, 2015», Revue Francophone des Laboratoires 2017, no 496 (novembre 2017): 66‑73.
[11]
Rosa Daza, José Gutiérrez, et Gonzalo Piédrola, «Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections», International Journal of Antimicrobial Agents 18, n° 3 (1 septembre 2001): 211‑15.
[12]
Hande Arslan et al., «Risk Factors for Ciprofloxacin Resistance among Escherichia Coli Strains Isolated from Community-Acquired Urinary Tract Infections in Turkey», Journal of Antimicrobial Chemotherapy 56, no 5 (1 novembre 2005): 914‑18.
[13]
I. Lahlou Amine, M. Chegri, et H. L’ Kassmi, «Épidémiologie et résistance aux antibiotiques des entérobactéries isolées d’ infections urinaires à l’hôpital militaire Moulay-Ismail de Meknès», Antibiotiques 11, no 2 (mai 2009): 90‑96.
[14]
A. Ferjani et al., «Caractéristiques épidémiologiques et bactériologiques des bactéries uropathogènes isolées dans un milieu pédiatrique», Archives de Pédiatrie 18, no 2 (février 2011): 230‑34. A.
[15]
M. Moutachakkir et al., «La résistance aux antibiotiques chez les entérobactéries uropathogènes en milieu pédiatrique au CHU de Marrakech», Journal de Pédiatrie et de Puériculture 28, no 1 (février 2015): 16‑22.
[16]
Eric Batard et al., «De la consommation d’antibiotiques aux résistances bactériennes : l’exemple de la résistance d’Escherichia coli aux quinolones» 17 (2011): 8.
[17]
Méril Massot, Bertrand Picard, et Erick Denamur, «Diversité des populations d’Escherichia coli et leurs variations au cours du temps au sein du microbiote intestinal», Revue Francophone des Laboratoires 2016, no 486 (novembre 2016): 35‑43.
[18]
A. Hounsa, L. Kouadio, et P. De Mol, «Automédication par les antibiotiques provenant des pharmacies privées de la ville d’Abidjan en Côte d’Ivoire », Médecine et Maladies Infectieuses 40, no 6 (juin 2010): 333‑40.
[19]
Gustavo A. Vasquez et al., «Risk Factors for Quinolone-Resistant Escherichia Coli Urinary Tract Infection», Infectious Diseases in Clinical Practice 17, no 5 (septembre 2009): 309‑13.
[20]
P. Nordmann et H. Mammeri, «Résistance plasmidique aux quinolones», Antibiotiques 9, no 4 (décembre 2007): 246-53.
[21]
Philippe RS Lagacé-Wiens et al., «ESBL Genotypes in Fluoroquinolone-Resistant and Fluoroquinolone-Susceptible ESBL-Producing Escherichia Coli Urinary Isolates in Manitoba», Canadian Journal of Infectious Diseases and Medical Microbiology 18, no 2 (2007): 133‑37.
[22]
N. Guessennd et al., «Résistance aux quinolones de type qnr chez les entérobactéries productrices de bêta-lactamases à spectre élargi à Abidjan en Côte d’Ivoire», Pathologie Biologie 56, no 7‑8 (novembre 2008): 439‑46.
Browse journals by subject